biologic

Carvykti

ciltacabtagene autoleucel

Loss of exclusivity—loss of exclusivity
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameCarvykti
Active ingredientciltacabtagene autoleucel
Strength0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.